Bradway’s patient dealmaking brings Onyx to Amgen

Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen’s successful acquisition of Onyx Pharmaceuticals for more than US$10 billion.

via Business feed http://www.scmp.com/business/companies/article/1299692/bradways-patient-dealmaking-brings-onyx-amgen